secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001655759-24-000128
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q3 2024 revenue $102.4M; cash $1.12B; VERITAC-2 data on track 4Q24/1Q25
-------------------------------------------------------------------------------

- Q3 revenue $102.4M (vs $34.6M YoY) mainly from Novartis license $76.7M.
- Cash and marketable securities $1.12B; sufficient to fund operations into 2027.
- R&D $86.9M; G&A $75.8M incl. $43.4M lease termination loss.
- VERITAC-2 Phase 3 topline data on track for 4Q24/1Q25; abemaciclib data at SABCS Dec 2024.
- ARV-102 MAD portion started; KRAS G12D IND filing expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/0001655759-24-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000128/arvn-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer